PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage "PICASSO"
Recruiting
Phase 4 Results N/ASummary of Purpose
Through this study, the investigators are to prove that Cilostazol effectively prevent cardiovascular events in ischemic stroke patients with high risk of cerebral hemorrhage, along with no significant increase in the risk of occurrence of hemorrhagic side effects. The primary hypothesis of this study is; Cilostazol alone or with probucol will reduce the risk of cerebral hemorrhage without increase of...
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 25 January 2012.
| 1 Jun 2009 | 10 Nov 2009 | 1 Dec 2013 | 1 Aug 2014 | 1 Nov 2009 | Unavailable |
| Start Date | First Received | 1st Completion | Completion | Verification | Results |
|---|
Trial Design
- Allocation: Randomized
- Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
- Purpose: Prevention
- Endpoint: Safety/Efficacy Study
- Intervention: Factorial Assignment
Contacts
- Sun U. Kwon, MD, PhD
View Trial Locations
Recruitment
- Enrollment: 1,592
- Gender: Both
- Minimum Age: 20 Years
- Accepts Healthy Volunteers: No
- 77 locations, 2 countries
Principal Investigator
- Sun U. Kwon, MD, PhD
Departement of Neurology, Asan Medical Center
